MedGenesis Therapeutix Reacquires Rights for GDNF
Published: Nov 08, 2010
VICTORIA, BRITISH COLUMBIA--(Marketwire - November 08, 2010) - MedGenesis Therapeutix Inc. ("MedGenesis"), announced today that it has regained all rights to glial cell line-derived neurotrophic factor (GDNF) protein and related Convection Enhanced Delivery (CED) technology from Biovail Laboratories International SRL ("BLS"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE and TSX: VRX). MedGenesis and BLS agreed to conclude their previously established collaboration to develop and commercialize GDNF, returning the product to MedGenesis together with a one-time cash payment of $5 million to accelerate the development of GDNF in Parkinson's disease. At the same time, MedGenesis has broadened GDNF applications to hearing loss and epilepsy.
MedGenesis Therapeutix Inc.
Chief Financial Officer